| NCT ID | NCT06637644 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abiomed Inc. |
| Condition | Right Ventricular (RV) Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-05-29 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-05-29 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To capture observational data of the Abiomed Impella RP Flex in a real-world setting.
Eligibility Criteria
Inclusion Criteria: * Subjects who received mechanical circulatory support (MCS) with an Impella RP Flex will be considered eligible for the registry. Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06637644 clinical trial?
This trial is open to participants of all sexes, studying Right Ventricular (RV) Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06637644 currently recruiting?
Yes, NCT06637644 is actively recruiting participants. Contact the research team at shallawa@its.jnj.com for enrollment information.
Where is the NCT06637644 trial being conducted?
This trial is being conducted at Birmingham, United States, Tucson, United States, Little Rock, United States, Little Rock, United States and 11 additional locations.
Who is sponsoring the NCT06637644 clinical trial?
NCT06637644 is sponsored by Abiomed Inc.. The trial plans to enroll 200 participants.